Compare IQVIA Holdings Inc. Common Stock (IQV) vs QXO Inc. Common Stock (QXO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQVIA Holdings Inc. Common Stock vs QXO Inc. Common Stock — how do they compare? IQVIA Holdings Inc. Common Stock trades at $264.45 (market cap $42.91B), while QXO Inc. Common Stock trades at $10.33 (market cap $11.43B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 3.8× QXO Inc. Common Stock's market cap, and IQVIA Holdings Inc. Common Stock is trading nearer its 52-week high, QXO Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQVIA Holdings Inc. Common Stock for 6 Days and QXO Inc. Common Stock for 0 Days on average.
| IQV | QXO | |
|---|---|---|
Market Cap | $42.91B | $11.43B |
Volume | 1,333,456 | 21,645,941 |
Sector | Health | Industrials |
52-Week High | $275.02 | $27.07 |
52-Week Low | $156.66 | $10.33 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $57.07B | $16.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.
The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.
QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.
The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IQVIA Holdings Inc. Common Stock
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →About QXO Inc. Common Stock
QXO, Inc. is a distributor of roofing, insulation, waterproofing, and other building materials, serving contractors and builders across US and Canada through its network of branch locations.
Read more on QXO →
